Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC36712 structure
    GC36712Necrostatin 2 S enantiomer
    CAS: 852391-20-9
    纯度: >99.50%

    Necrostatin 2 S enantiomer 是 Necrostatin 2 的 S 型异构体。Necrostatin 2 是高活性的坏死性凋亡抑制剂,为有效的 RIPK1 抑制剂,缺乏 IDO 靶向作用。

  • GC36743 structure
    GC36743Nimustine hydrochloride
    CAS: 55661-38-6
    纯度: >98.00%

    A pyrimidine analog and nitrosourea alkylating agent

  • GC36747 structure
    GC36747Nitroaspirin
    CAS: 175033-36-0

    Nitroaspirin (NCX 4016) 是一氧化氮 (NO) 供体和阿司匹林的硝基衍生物,Aspirin 与 Nitroaspirin 联合以抑制环加氧酶。Nitroaspirin (NCX 4016) 具有抗血栓形成和抗血小板特性,并作为 COX-1 的直接和不可逆抑制剂。Nitroaspirin (NCX 4016) 通过下调 EGFR/PI3K/STAT3 信号传导和调节 Bcl-2 家族蛋白,在顺铂耐药人卵巢癌细胞中引起细胞周期停滞和凋亡。

  • GC36767 structure
    GC36767NP-12
    CAS: 1353563-85-5

    A PL-1/PD-L interaction inhibitor

  • GC36768 structure
    GC36768NP-12 (TFA)

    NP-12 (TFA) 是 PD-1 信号通路的一种多肽拮抗剂,在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。NP-12 (TFA) 具有免疫激活作用、良好的抗肿瘤活性,具有治疗免疫相关不良事件 (irAEs) 的潜力。

  • GC36773 structure
    GC36773Nrf2-IN-1
    CAS: 1610022-76-8
    纯度: >98.50% / >98.00%

    Nrf2-IN-1是nuclear factor-erythroid 2-related factor 2 (Nrf2)的抑制剂,用于急性髓系白血病(AML)的研究。

  • GC36785 structure
    GC36785NVP-CGM097 sulfate
    CAS: 1313367-56-4
    纯度: >98.50%

    An inhibitor of the MDM2-p53 interaction

  • GC36821 structure
    GC36821OSU-T315
    CAS: 2070015-22-2
    纯度: >98.00%

    OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).

  • GC36835 structure
    GC36835p53 and MDM2 proteins-interaction-inhibitor chiral
    CAS: 939981-37-0

    手性p53 and MDM2 proteins-interaction-inhibitor是p53和MDM2相互作用的抑制剂。

  • GC36836 structure
    GC36836p53 and MDM2 proteins-interaction-inhibitor dihydrochloride
    CAS: 2070009-27-5
    纯度: >99.50%

    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride 是p53与MDM2相互作用抑制剂。

  • GC36837 structure
    GC36837p53 and MDM2 proteins-interaction-inhibitor racemic
    CAS: 939983-14-9

    外消旋p53 and MDM2 proteins-interaction-inhibitor是p53与MDM2相互作用抑制剂。

  • GC36847 structure
    GC36847Pantoprazole sodium
    CAS: 138786-67-1
    纯度: >99.50%

    A proton pump inhibitor

  • GC36848 structure
    GC36848Pantoprazole sodium hydrate
    CAS: 164579-32-2
    纯度: >98.00%

    A proton pump inhibitor

  • GC36855 structure
    GC36855Paris saponin VII
    CAS: 68124-04-9
    纯度: >98.00% / >98.50%

    Chonglou Saponin VII (Dioscinin, Polyphyllin-VII, Paris saponin-VII), a kind of steroidal saponins from Chonglou (Rhizoma Paridis Chonglou), inhibits EMT and reduces the invasion of ovarian cancer cells via the GSK-3β/β-catenin signaling pathway.

  • GC36862 structure
    GC36862PD-1-IN-22
    CAS: 2349372-98-9

    PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1)/程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂,IC50 为 92.3 nM。

  • GC36865 structure
    GC36865PEAQX tetrasodium hydrate
    纯度: >98.00%

    PEAQX tetrasodium hydrate是一种强效且有口服活性的NMDA受体拮抗剂,对hNMDA 1A/2A和1A/2B受体的IC 50 值分别为0.270μM和29.6μM。

  • GC36892 structure
    GC36892PHA-767491 hydrochloride
    CAS: 942425-68-5
    纯度: >99.00% / >98.00%

    A potent Cdc7 kinase inhibitor

  • GC36895 structure
    GC36895Phenoxodiol
    CAS: 81267-65-4
    纯度: >98.00%

    Phenoxodiol是一种异黄酮衍生物,具有抗肿瘤活性。

  • GC36896 structure
    GC36896PhiKan 083 hydrochloride
    CAS: 1050480-30-2
    纯度: >99.00%

    PhiKan 083 hydrochloride 是一种咔唑衍生物,可以稳定 p53 的突变体 Y220C,Kd 值为 167 μM,在 Ln229 细胞中,相对亲和力 (Kd) 为 150 μM;PhiKan 083 可用于癌症研究。

  • GC36904 structure
    GC36904Phytohemagglutinin
    CAS: 9008-97-3
    纯度: >98.00%

    Phytohemagglutinin是一种源自植物的凝集素蛋白。

  • GC36920 structure
    GC36920Pimpinellin
    CAS: 131-12-4
    纯度: >98.00%

    Pimpinellin 是 Cyrtomium fortumei (J.) 的一种成分。Pimpinellin 通过诱导肿瘤细胞凋亡 (apoptosis) 抑制肿瘤细胞的生长。

  • GC36930 structure
    GC36930Pitavastatin D4
    CAS: 2070009-71-9

    Pitavastatin D4是Pitavastatin氘代化合物标准品。

  • GC36933 structure
    GC36933PK68
    CAS: 2173556-69-7
    纯度: >99.50%

    PK68 is a potent orally active and specific inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90?nM.

  • GC37010 structure
    GC37010PROTAC MDM2 Degrader-1
    CAS: 2249944-98-5
    纯度: >98.00%

    PROTAC MDM2 Degrader-1 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-1 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。